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INTRODUCTION 
Mycobacterium genavense was identified as one of the 
non-tuberculous mycobacteria in 1992 [1]. Since then, 
it had been reported to cause life threatening infection 
in  severely immunodeficient patients with human 
immunodeficiency virus (HIV) infection [1]. In HIV-
negative patients, disseminated M. genavense infection 
had also been reported, however, these patients were 
usually in immunocompromised state, such as those 
with long-standing chronic lymphocytic leukaemia [2], 
those undergoing immunosuppressive therapy [3] and 
solid organ transplant recipients [4]. To the best of our 
knowledge, there had only been 2 cases of M. 
genavense infection reported in healthy individuals [5, 
6]. 
 
CASE PRESENTATION 
A 70-year-old lady with type 2 diabetes mellitus 
(HbA1c of 6.7%), ischaemic heart disease, bronchial 
asthma (controlled with fluticasone/salmeterol inhaler 
combination and theophylline), and history of right 
total mastectomy with chemotherapy for right breast 
cancer 20 years ago, was referred to respiratory team 
in December 2013 with an incidental finding of a 
cavitating left lung mass found during cardiac MRI. 
Subsequent CT thorax showed a lung lesion with 
multiple cavities (see picture). Bronchial washing and 
bronchoalveolar lavage were negative for acid fast 
bacilli, culture did not grow any organism, and 
cytology were negative for malignancy. Two 
sequential CT thorax 6-month apart showed a 
relatively similar lesion in size and characteristic.  
 A year later, she presented again with 2 
months worsening cough, associated with occasional 
haemoptysis, night sweats, and significant weight loss. 
Physical examination of the lungs showed no 
abnormality and no cervical or axillary 
lymphadenopathies. Cardiovascular and abdominal 
examinations were unremarkable. Full blood count, 
liver function test and renal profile were within the 
normal range. Erythrocyte sedimentation rate were 
only slightly elevated. Screening for HIV, Hepatitis B 
and C were all negative. Sputum acid fast bacilli were 
positive 1+ on two occasions. In view of the symptoms 
and positive sputum smear for AFB, she was 
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commenced on a fixed dose combination of 
rifampicin, isoniazid, ethambutol, and pyrazinamide 
(Akurit-4). After 21 days of treatment she improved in 
that her weight increased and the cough frequency 
reduced. Sputum culture at the start of treatment 
confirmed M. genavense. Unfortunately, she 
developed drug induced hepatitis with intractable 
vomiting after 1 month of treatment with ALT 505 
U/L, AST 677 U/L, total bilirubin 71 mg/dL, and GGT 
196 U/L which resolved after withholding Akurit-4. 
She denied concurrent consumption of traditional 
medications or other hepatotoxic drugs.  
 After two months of treatment, the sputum for 
acid-fast-bacilli was still positive. On this occasion the 
sputum culture again grew M. genavense. In view of 
these, we decided to re-challenge her with 
clarithromycin, rifampicin, and ofloxacin. Full dose of 
each drug (rifampicin 450mg once daily, ofloxacin 
400mg twice daily and clarithromycin 500mg twice 
daily) was achieved within 2 months. At 3 months, 
sputum acid fast bacilli were still heavily positive. 
Molecular Line Probe Assay of her sputum sample did 
not detect the presence of mycobacterium gene and the 
Gene Xpert MTB/RIF showed no resistant organism. 
She developed vomiting with the medications. 
However, in view of the heavily positive AFB smear 
which grew M. genavense twice, and persistence of 
initial symptoms, we decided to continue the treatment 
regime under strict supervision.  
 In September 2015, after 9 months of 
uninterrupted treatment, she continued to have 
vomiting and dizziness, in which neither anti emetics 
nor adjusting the dose of the medications help to 
relieve her symptoms. She lost about 8 kilograms in 
weight due to vomiting and her quality of life was 
much reduced. At this point, the repeat sputum acid 
fast bacilli became negative and therefore a decision 
was made to stop the treatment. One month after 
stopping treatment, she felt better, the side effects 
subsided, her appetite improved and she gained weight 
by 2 kilograms. At the last clinic review about 2 years 
after treatment discontinuation, she remained well, and 
was only occasionally troubled by her asthma. 
 
 
 
DISCUSSION 
In 1992, fastidious organism of Mycobacterium 
genavense has been described to cause disseminated 
infections in patients infected by Human 
Immunodeficiency Virus (HIV) [7]. 
 
 
Figure 1 CT thorax showed a lung lesion with multiple cavities; 
some of which show air-fluid level seen, at the upper segment of 
the left lower lobe. This lesion measures 4.6 (AP) x 4.7 (W) x 5.9 
(CC) cm.  
 
 After the introduction of anti-retroviral agents, 
the epidemiology of the pathogen had changed. 
Disseminated infections of M. genavense were 
reported in non-HIV patients who were severely 
immunocompromised [2-4]. Most of the patients with 
disseminated M. genavense infection have similar 
clinical symptoms as those of Mycobacterium avium 
complex, characterised by fever, diarrhoea, weight 
loss, anaemia and lymphadenopathy [8]. 
 Mycobacterium genavense has rarely been 
isolated from the gastrointestinal tract of healthy 
individuals [9]. Hence it is important to distinguish 
between colonization and true infection. Two cases of 
M. genavense in healthy immunocompetent patients 
have been reported. The first case was reported in 
1995, a 41 year old woman with severe lymphadenitis 
caused by a fastidious mycobacterium closely related 
to M. genavense, whose brother had died from an 
unidentified mycobacterial infection 20 years back [5]. 
The second case was reported in 2010, a case of 
disseminated M. genavense in a healthy 15 year old 
Japanese boy, who developed tumorous lesions in the 
gastrointestinal tract resulting in stenosis of ileocecal 
valve [6]. 
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 Our patient had symptoms suggestive of 
pulmonary tuberculosis. Her sputum was positive for 
acid fast bacilli and sputum culture grew M. genavense 
twice. She was not in an immunocompromised state. 
Her diabetic control was good with HbA1c of 6.7%, 
she required oral prednisolone only during her asthma 
exacerbation that occurred once or twice a year, and 
the chemotherapy for her breast cancer was 20 years 
ago. We commenced anti-tuberculous treatment and 
her symptoms improved. However, she could not 
tolerate the side effects of the treatment, hence the 
dilemma of her management started. 
 As we know, there is no standard treatment for 
M. genavense infection. In the first case by Bosquee et 
al, the patient responded to combination of rifabutin 
(150mg b.i.d.), clofazimine (100mg b.i.d.), 
clarithromycin (1g b.i.d.), and ethambutol (1200 mg 
daily) that were prescribed for 10 months [5]. In the 
second case, the patient responded to combination of 
clarithromycin, ethambutol and rifampicin (the dosage 
and duration were not stated in the case report) [6]. In 
another study on non-tuberculous mycobacterium 
(NTM), susceptibility testing showed that M. 
genavense is sensitive to rifampicin, fluoroquinolones, 
and macrolides [10]. For our patient we have decided 
to treat the patient with rifampicin, ofloxacin and 
clarithromycin.  
 This case illustrates the importance of 
identifying a rare and unique NTM infection, 
especially in our population with high index of 
tuberculosis prevalence. NTM may provide confusion 
in deciding our initial treatment plan for smear positive 
patients. Given the higher prevalence of 
mycobacterium tuberculosis in our population, in 
clinical practise, smear positive acid-fast bacilli 
specimens will be treated presumptively with standard 
anti-tuberculosis treatment for 2 months, until the 
culture results revealed the true nature of the 
Mycobacterium species. 
CONCLUSION  
This is the first case of pulmonary M. genavense 
infection reported in Malaysia, and it occurred in an 
immunocompetent patient. The treatment guidelines 
for M. genavense are not well-established, unlike other 
NTM such as M. abcessus and M. avium complex. The 
decision on the treatment option and duration has to be 
tailored on case by case basis. It is important to find 
balance between treating the disease and managing the 
side effects of the treatment. Cure is not always the 
objective if it meant compromising the patient’s 
wellbeing and therefore no treatment is sometimes the 
best option. If the disease did not compromise the 
patient’s well-being and that the treatment caused 
severe side effects, one might have to consider 
withholding treatment and opt for watchful waiting. 
More data and experiences are needed to help manage 
infections by NTM which remains unexplored, 
especially in Malaysian population. 
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